Introduction: Cancer and myocardial infarction are lethal diseases. Their prevalence is increasing worldwide. In both diseases, the level of oxidative stress rises because of tissue damage. The aim of this study was to evaluate the serum levels of heat shock protein 27 and heat shock protein 60 in patients with cancer and myocardial infarction, and then compare them with healthy individuals.
Materials and Methods: After blood samples were collected from the participants, plasma and serum were separated from these samples for further examination. The serum levels of heat shock protein 27 and heat shock protein 60 were measured with related kits in 30 patients with cancer and 30 patients with acute myocardial infarction, followed by 30 healthy individuals. The collected data were then analyzed in the Statistical Package for the Social Sciences software (version 22).
Results: The mean serum levels of heat shock protein 27 in cancer patients (25.21 ± 5.57 ng/mL) and in patients with myocardial infarction (45.23 ± 7.43) were significantly higher than those in healthy individuals (10.61 ± 3.11; P<.05). In addition, the mean serum levels of heat shock protein 60 in patients with cancer (19.23 ± 3.41 ng/mL) and patients with myocardial infarction (22.23 ± 2.25 ng/mL) were significantly higher than those in healthy individuals (8.38 ± 2.53; P<.05).
Conclusion: An increase in the serum levels of heat shock proteins 27 and 60 was observed in patients with cancer and myocardial infarction. Therefore, we can suggest that these biomarkers should help surgeons or physicians to diagnose the diseases.
Almasi A, Shamsi M, BabakEshrati RF, Alimoradi K, Rahmati L. The epidemiology of gastrointestinal cancers (Stomach, esophageal, colorectal) In Markazi province during 2005-2010. Journal of Neyshabur University Medical Sciences. 2014;2(2):22-7.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017;67(3):177-93.
Rafiemanesh H, Rajaei-Behbahani N, Khani Y, Hosseini S. Incidence trend and epidemiology of common cancers in the center of Iran. Global journal of health science. 2016;8(3):146.
Foadoddini M, Amir-Abadi Zadeh M, Ghiravani Z. Cardioprotective effects of ranitidine against ischemia-reperfusion injury in mice. Journal of Birjand University of Medical Sciences. 2014;20(4):346-56.
Okuno M, Yasuda I, Adachi S, Nakashima M, Kawaguchi J, Doi S, et al. The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. Oncotarget. 2016;7(12):14291.
Giaginis C, Daskalopoulou SS, Vgenopoulou S,Sfiniadakis I, Kouraklis G, Theocharis SE. Heat Shock Protein-27,-60 and-90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC gastroenterology. 2009;9(1):14.
Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegård J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension. 2000;36(2):303-7.
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell stress & chaperones. 2005;10(2):86-103.
King KL, Li AFY, Chau GY, Chi CW, Wu CW, Huang CL, et al. Prognostic significance of heat shock protein‐27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer. 2000;88(11):2464-70.
Madrigal-Matute J, Martin-Ventura JL, Blanco-Colio LM, Egido J, Michel J-B, Meilhac O. Heat-shock proteins in cardiovascular disease. Advances in clinical chemistry. 2011;54:3.
Abharzanjani F, Kazemi T, Bijari B, Hemmati M. Comparison of serum level of heat shock protein 27 (HSP 27) and the amount of DNA damage in acute myocardial infarction patients. Iranian Journal of Endocrinology and Metabolism. 2016;18(4):243-50.
Gharibdoost F, Samadi F, Taghipoor R, Akbarian M, Shahram F, Nadji A, et al. Heat shock protein 70 level of synovial fluid in rheumatoid arthritis versus osteoarthritis: a comparative study. Tehran University Medical Journal TUMS Publications. 2007;65(7):28-31.
Zhang X, He Ma, Cheng L, Chen Y, Zhou L, Zeng H, et al. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. Circulation. 2008;118(25):2687-93.
De Haan J, Smeets M, Pasterkamp G, Arslan F. Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediators of Inflammation. 2013;2013.
Hamelin C, Cornut E, Poirier F, Pons S, Beaulieu C, Charrier JP, et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. The FEBS journal. 2011;278(24):4845-59.
Li X-s, Xu Q, Fu X-y, Luo W-s. Heat shock protein 60 overexpression is associated with the progression and prognosis in gastric cancer. PloS one. 2014;9(9):e107507.
Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. European journal of cancer. 2004;40(18):2804-11.
Cappello F, Di Stefano A, D'Anna SE, Donner CF, Zummo G. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis. The lancet oncology. 2005;6(10):816.
Eto D, Hisaka T, Horiuchi H, Uchida S, Ishikawa H, Kawashima Y, et al. Expression of HSP27 in Hepatocellular Carcinoma. Anticancer research. 2016;36(7):3775-9.
Kuramitsu Y, Wang Y, Taba K, Suenaga S, Ryozawa S, Kaino S, et al. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer research. 2012;32(6):2295-9.
This work is licensed under a Creative Commons Attribution 4.0 International License.